Search

The article present a study indicating that piperacillin-tazobactam and cefepime are equally safe in terms of acute kidney injury (AKI) in adults with acute infection, with cefepime being associated with more neurological issues. It discusses about no significant difference in the risk of the highest stage of AKI or death within 14 days between the cefepime and piperacillin-tazobactam group; and suggesting that piperacillin-tazobactam poses no renal risk in this population.

Piperacillin and tazobactam could treat pediatric cancer patients with febrile neutropenia. "The purpose of this study was to compare the efficacy, safety, and cost of piperacillin/tazobactam with cefepime monotherapy in [...]